

# Lyme disease and Pregnancy

Epidemiology and Pathobiology of *Borrelia*:

Implications for Research

Holly Ahern, MS, MT(ASCP)

Associate Professor of Microbiology, State University of New York, Adirondack [ahernh@sunyacc.edu](mailto:ahernh@sunyacc.edu)

Vice-President Lyme Action Network ([www.lymeactionnetwork.org](http://www.lymeactionnetwork.org))

Scientific Advisor for Focus on Lyme ([www.focusonlyme.org](http://www.focusonlyme.org))

Advisory Board for Mothers Against Lyme ([www.mothersagainstlyme.org](http://www.mothersagainstlyme.org))


Mom

# The Global Impact of Lyme disease



# Number of cases of notifiable vector-borne diseases in the U.S. in 2018, by disease

Number of cases of vector-borne disease U.S. 2018, by disease



**Note(s):** United States

Further information regarding this statistic can be found on page 8.

**Source(s):** CDC (NNDSS); [ID\\_742326](#)



## The Lyme Disease Biobank: Characterization of 550 Patient and Control Samples from the East Coast and Upper Midwest of the United States

Elizabeth J. Horn,<sup>a</sup> George Dempsey,<sup>b</sup> Anna M. Schotthoefer,<sup>c</sup> U. Lena Prisco,<sup>d\*</sup> Matthew McArdle,<sup>e</sup> Stephanie S. Gervasi,<sup>f</sup> Marc Golightly,<sup>g</sup> Cathy De Luca,<sup>h</sup> Mel Evans,<sup>i</sup> Bobbi S. Pritt,<sup>j</sup> Elitza S. Theel,<sup>k</sup> Radha Iyer,<sup>l</sup> Dionysios Liveris,<sup>l</sup> Guiqing Wang,<sup>l</sup> Don Goldstein,<sup>l</sup> Ira Schwartz<sup>l</sup>

<sup>a</sup>Lyme Disease Biobank, Portland, Oregon, USA

<sup>b</sup>East Hampton Family Medicine, East Hampton, New York, USA

<sup>c</sup>Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA

<sup>d</sup>Vineyard Center for Clinical Research, Martha's Vineyard, Massachusetts, USA

<sup>e</sup>Department of Pathology, Stony Brook University, Stony Brook, New York, USA

<sup>f</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

<sup>g</sup>Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, USA

**ABSTRACT** Lyme disease (LD) is an increasing public health problem. Current laboratory testing is insensitive in early infection, the stage at which appropriate treatment is most effective in preventing disease sequelae. The Lyme Disease Biobank (LDB) collects samples from individuals with symptoms consistent with early LD presenting with or without erythema migrans (EM) or an annular, expanding skin lesion and uninfected individuals from areas of endemicity. Samples were collected from 550 participants (298 cases and 252 controls) according to institutional review board-approved protocols and shipped to a centralized biorepository. Testing was performed to confirm the presence of tick-borne pathogens by real-time PCR, and a subset of samples was tested for *Borrelia burgdorferi* by culture. Serology was performed on all samples using the CDC's standard two-tiered testing algorithm (STTTA) for LD. LD diagnosis was supported by laboratory testing in 82 cases, including positive results by use of the STTTA, PCR, or culture or positive results by two enzyme-linked immunosorbent assays for cases presenting with EM lesion sizes of >5 cm. The remaining 216 cases had negative laboratory testing results. For the controls, 43 were positive by at least one of the tiers and 6 were positive by use of the STTTA. The results obtained with this collection highlight and reinforce the known limitations of serologic testing in early LD, with only 29% of individuals presenting with EM lesion sizes of >5 cm yielding a positive result using the STTTA. Aliquots of whole blood, serum, and urine from clinically characterized patients with and without LD are available to investigators in academia and industry for evaluation or development of novel diagnostic assays for LD, to continue to improve upon currently available methods.

**KEYWORDS** biobank, biorepository, Lyme disease, serology, diagnostics

The Lyme Disease Biobank (LDB) is a collection of human biological samples that facilitates research in Lyme disease (LD) and other tick-borne infections (TBI). The LDB was created in 2014 to provide well-characterized samples to investigators working to develop more accurate diagnostic tests for LD. In the United States, LD is caused primarily by the bacterium *Borrelia burgdorferi sensu stricto*, transmitted to a host through the blood meal of an infected Ixodes tick (1). Humans are incidental hosts and not part of the enzootic cycle. In the Upper Midwest, *Borrelia mayonii* is responsible for

**Citation** Horn EJ, Dempsey G, Schotthoefer AM, Prisco UL, McArdle M, Gervasi SS, Golightly M, De Luca C, Evans M, Pritt BS, Theel ES, Iyer R, Liveris D, Wang G, Goldstein D, Schwartz I. 2020. The Lyme Disease Biobank: characterization of 550 patient and control samples from the East Coast and Upper Midwest of the United States. J Clin Microbiol 58:e00032-20. <https://doi.org/10.1128/JCM.00032-20>

**Editor** Brad Ferwick, University of Tennessee at Knoxville

**Copyright** © 2020 Horn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Elizabeth J. Horn, info@lymebiobank.org.

\*Present address: U. Lena Prisco, Prisco Clinical and Scientific Consulting, Martha's Vineyard, Massachusetts, USA.

For a commentary on this article, see <https://doi.org/10.1128/JCM.00449-20>.

**Received** 6 January 2020

**Returned for modification** 27 January 2020

**Accepted** 15 February 2020

**Accepted manuscript posted online** 26 February 2020

**Published** 26 May 2020

Downloaded from <https://jcm.asm.org/> on April 24, 2021 by guest

- “A lack of provider awareness of the **absence of EM or nonclassical EM presentations can lead to underdiagnosis and delayed treatment**, highlighting the need for better diagnostics for early LD.”
- “Insufficiencies in current testing methodologies **complicate the accurate diagnosis of early LD, contribute to delays in diagnosis and treatment**, and may result in additional sequelae.”
- The results obtained with this collection highlight and **reinforce the known limitations of serologic testing in early LD, with only 29% of individuals** presenting with EM lesion sizes of >5 cm yielding a positive result using the STTTA.

Article

## Course and Outcome of Erythema Migrans in Pregnant Women

Vera Manaspin<sup>1</sup>, Lara Lusa<sup>2,3</sup>, Tanja Blejcec<sup>4</sup>, Eva Ružič-Sabljic<sup>5</sup>, Maja Pohar Perme<sup>4</sup>  
and Franc Strle<sup>1,6\*</sup>

<sup>1</sup> Department of Infectious Diseases, University Medical Center Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia; vera.manaspin@uklj.si

<sup>2</sup> Department of Mathematics, Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Glagoljaška 8, 6000 Koper, Slovenia; lara.lusa@famnit.upr.si

<sup>3</sup> Institute for Biostatistics and Medical Informatics, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia; maja.pohar@mf.uni-lj.si

<sup>4</sup> Department of Perinatology, University Medical Center Ljubljana, Štajerskega vilsca 6a, 1525 Ljubljana, Slovenia; tanja.blejcec@gmail.com

<sup>5</sup> Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia; eva.ruzic-sabljic@mf.uni-lj.si

\* Correspondence: franc.strle@uklj.si; Tel.: +386-1-522-21-10

Received: 3 July 2020; Accepted: 23 July 2020; Published: 24 July 2020



**Abstract:** Information on Lyme borreliosis (LB) during pregnancy is limited. In the present study, the course and outcome of erythema migrans (EM) in 304 pregnant women, diagnosed in the period 1990–2015, was assessed and compared with that in age-matched non-pregnant women. The frequency of unfavorable outcome of pregnancies was also evaluated. The pregnant women reported constitutional symptoms less frequently than the non-pregnant women (22.4% vs. 37.2%,  $p < 0.001$ ). Pregnant women diagnosed with EM later during pregnancy had a lower probability of reporting constitutional symptoms (odds ratio = 0.97 for 1-week difference in gestation week at diagnosis of EM, 95% CI: 0.94–0.99,  $p = 0.02$ ). The outcome of pregnancy was unfavorable in 42/304 (13.8%) patients: preterm birth in 22/42 (52.4%), fetal/perinatal death in 10/42 (23.8%), and/or anomalies in 15/42 (35.7%). Several patients had potential explanation(s) for the unfavorable outcome. In conclusion, the course of early LB during pregnancy is milder than in age-matched non-pregnant women. The outcome of pregnancy with the treatment approach used in the present study (i.v. ceftriaxone 2 g once daily for 14 days) is favorable.

**Keywords:** erythema migrans; Lyme borreliosis; gestation; pregnancy outcome; *Borrelia burgdorferi sensu lato*

### 1. Introduction

Lyme borreliosis (LB) usually presents as the skin lesion erythema migrans (EM). The lesion, which is the result of tick bite inoculation of *Borrelia burgdorferi sensu lato* (s.l.) into the skin, develops early in the course of the disease. The causative agent can disseminate in some patients, resulting in secondary skin lesions and involvement of the nervous system, joints, heart, and/or eye [1].

Information on LB during pregnancy is limited. According to general belief, there are no differences in the course of the disease in pregnant and non-pregnant women. However, a PubMed literature search has found no straightforward data on the course of the infection in pregnant women, and information on the outcome of their pregnancies is limited [2–23].

The aim of our study was to evaluate and compare the course and outcome of early LB in non-pregnant and pregnant women and to assess the outcomes of the pregnancies.

**“Pregnant woman women less often had a ring-like EM (42.4% vs. 55.3%,  $p = 0.002$ ), less often had EM located on the trunk (14.1% vs. 24.0%,  $p = 0.009$ ), and less often reported constitutional symptoms (22.4% vs. 37.2%,  $p < 0.001$ ).”**

“We do not have a reliable explanation for the observation that the pregnant women less often had ring-like EM despite similar duration of the skin lesion before treatment, **but we stress that the findings in our control group are in agreement with previous reports.**”

“Most manifestations of LB result from inflammation generated by the host immune response to the spirochete. **Thus, fewer symptoms, as found in the present study of pregnant women with EM, may be associated with lower levels of inflammation.**

https://www.cdc.gov/lyme/stats/humancases.html



## Lyme Disease

[CDC](#) > [Lyme Disease Home](#) > [Data and surveillance](#)



 [Lyme Disease Home](#)

[Preventing tick bites](#) +

[Tick removal and testing](#)


[Transmission](#)

# How many people get Lyme disease?

There is no way of knowing exactly how many people get Lyme disease. A recently released estimate based on insurance records suggests that each year approximately 476,000 Americans are *diagnosed and treated* for Lyme disease.<sup>1,2</sup> This number is likely an over-estimate of actual infections because patients are sometimes treated presumptively in medical practice. Regardless, this number indicates a large burden on the health care system and the need for more effective prevention measures.

*“A recently released estimate based on insurance records suggests that **each year approximately 476,000 Americans are diagnosed and treated for Lyme disease.**”*

# Comparing Annual Cases of STDs to Lyme disease




<https://www.cdc.gov/nchs/hus/contents2019.htm#Table-010>

## Considerations

- Case numbers of other vector-borne diseases show that ticks are not great vectors.
- Distribution of vectors in US:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844559/>



- Data strongly suggests **other routes of transmission**
- Data also suggests **humans have become reservoir hosts**

## Congenital Tick Borne Diseases: Is This An Alternative Route of Transmission of Tick-Borne Pathogens In Mammals?

Krzysztof P. Jaski<sup>1</sup>, Hubert Okla<sup>1,2</sup>, Jan Słodki<sup>1</sup>, Beata Rozwadowska<sup>1,3</sup>,  
Aleksandra Słodki<sup>1</sup>, and Weronika Rupilik<sup>4</sup>

### Abstract

Tick-borne diseases (TBDs) have become a popular topic in many medical journals. Besides the obvious participation of ticks in the transmission of pathogens that cause TBD, little is written about alternative methods of their spread. An important role is played in this process by mammals, which serve as reservoirs. Transplacental transfer also plays important role in the spread of some TBD etiological agents. Reservoir species take part in the spread of pathogens, a phenomenon that has extreme importance in synanthropic environments. Animals that accompany humans and animals migrating from wild lands to urban areas increase the probability of pathogen infections by ticks. This article provides an overview of TBDs, such as tick-borne encephalitis virus (TBEV), and TBDs caused by spirochetes,  $\alpha$ -proteobacteria,  $\gamma$ -proteobacteria, and Apicomplexa, with particular attention to reports about their potential to cross the maternal placenta. For each disease, the method of propagation, symptoms of acute and chronic phase, and complications of their course in adults, children, and animals are described in detail. Additional information about transplacental transfer of these pathogens, effects of congenital diseases caused by them, and the possible effects of maternal infection to the fetus are also discussed. The problem of vertical transmission of pathogens presents a new challenge for medicine. Transfer of pathogens through the placenta may lead not only to propagation of diseases in the population, but also constitute a direct threat to health and fetal development. For this reason, the problem of vertical transmission requires more attention and an estimation of the impact of placental transfer for each of listed pathogens.

**Key Words:** Tick-borne diseases—Congenital diseases—Transplacental transmission.

### Introduction

**D**URING THE LAST 30 YEARS, much attention has been paid to diseases transmitted by ticks—tick-borne diseases (TBDs). There is an extensive literature describing this issue, usually epidemiologically, and drawing attention to the methods of how the various pathogens are spread. Ticks function as vectors, but animals that are their reservoirs play an important role as well. Many publications describe the phenomenon of pathogen transfer between vectors—ticks—which can be done by co-feeding and vertically by germ cells.

Relatively few publications describe cases of pregnant mother and newborn infections, pointing out another possibility of TBD pathogens spread by penetration through the placenta of infected animals and humans, in other words, the possibility of intergenerational infection. A properly developed placenta is supposed to be a selective barrier through which, theoretically, no pathogens should cross. However, this is not true. Clinical observations have provided information about etiological factors of congenital diseases that cross the placental barrier, thus confirming the transplacental transmission of such pathogens as viruses, bacteria, and protozoa (Robbins and Bakardjiev 2012).

“Despite the fact that some authors consider that antibiotic therapy of a pregnant mother diagnosed with Lyme disease allows normal development of the child (Walsh et al. 2007, Leslein 2010), it must be kept in mind that the treatment of Lyme disease is sometimes long and difficult (Embers et al. 2012). ***The ability of long-term survival of *B. burgdorferi* in tissues and spreading of spirochetes in the body despite antibiotic treatment can contribute to intergenerational infection of Lyme disease.***”

<sup>1</sup>Department of Skin Structural Studies, Medical University of Silesia in Katowice, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Sosnowiec, Poland.

<sup>2</sup>University of Silesia in Katowice, Faculty of Computer Science and Material Science, Institute of Material Science, Katowice, Poland.

<sup>3</sup>Provincial Sanitary and Epidemiological Station in Katowice, Katowice, Poland.

<sup>4</sup>Department of Animal Histology and Embryology, University of Silesia in Katowice, Faculty of Biology and Environmental Protection, Katowice, Poland.

## Animal Studies Showing Vertical Transmission of *Borrelia burgdorferi*

- 1 Anderson JF, Johnson RC, Magnarelli LA. Seasonal prevalence of *Borrelia burgdorferi* in natural populations of white-footed mice, *Peromyscus leucopus*. *Journal of Clinical Microbiology*, Vol 25(8)Aug, 1987, p. 1564-1566.
- 2 Experimental and epizootiologic studies of Lyme disease Ubico-Navas, Sonya Renee, Ph.D. Colorado State University, 1992.
- 3 Burgess EC, Wachal MD, Cleven TD. *Borrelia burgdorferi* infection in dairy cows, rodents, and birds from four Wisconsin dairy farms. *Vet Microbiol.* 1993 May;35(1-2):61-77. doi: 10.1016/0378-1135(93)90116-o. PMID: 8362496.
- 4 Silver RM, Yang L, Daynes RA, Branch DW, Salafia CM, Weis JJ. Fetal outcome in murine Lyme disease. *Infect Immun.* 1995;63(1):66-72. doi:10.1128/IAI.63.1.66-72.1995
- 5 Altaie SS, Mookherjee S, Assian E, Al-Taie F, Nakeeb SM, Siddiqui SY. Transplacental transmission of Bb in a Murine Model. 10<sup>th</sup> Annual International Scientific Conference on Lyme Disease and other Tick-Borne Disorders, National Institutes of Health, Bethesda MD April 28-30, 1997.
- 6 Hou X. [Preliminary investigation on reservoir hosts of *Borrelia burgdorferi* in China]. *Wei Sheng Yan Jiu.* 1999 Jan 30;28(1):7-9. Chinese. PMID: 12712735.
- 7 Burgess EC. *Borrelia burgdorferi* infection in Wisconsin horses and cows. *Ann N Y Acad Sci.* 1988;539:235-43. doi: 10.1111/j.1749-6632.1988.tb31857.x. PMID: 3190095.
- 8 Leibstein MM, Khan MI, Bushmich SL. Evidence for in-utero Transmission of *Borrelia burgdorferi* from Naturally Infected Cows. *Journal of Spirochetal and Tick-borne Diseases.* Vol 5, Fall/Winter, 1998: 54-62.
- 9 Burgess EC, Gendron-Fitzpatrick A, Mattison M. Foal mortality associated with natural infection of pregnant mares with *Borrelia burgdorferi*. In *Proceedings, 5th Int Conf Equine Infectious Dis*, 1989, 217-220.
- 10 Gustafson, John Michael, Ph.D. The in utero and seminal transmission of *Borrelia burgdorferi* in Canidae. The University of Wisconsin - Madison, 1993. PhD Thesis.
- 11 Gustafson JM, Burgess EC, Wachal MD, Steinberg H. Intrauterine transmission of *Borrelia burgdorferi* in dogs. *Am J Vet Res.* 1993 Jun;54(6):882-90.
- 12 Burgess EC, Windberg LA. *Borrelia* SP. Infection in coyotes, black-tailed Jack rabbits and desert cottontails in Southern Texas. *Journal of Wildlife Diseases* 25(1), 1989, pp. 47-51.

“It is possible that ***non-arthropod transmission could introduce the spirochete into populations outside of the geographical range of the tick vector***. The apparent ease by which organisms can be transmitted by these mechanisms demands closer inspection if the overall epidemiologic and epizootiologic picture is to be understood.” – Gustafsen, 1993

“If ***fetuses can be infected in-utero with B. burgdorferi, as suggested by Anderson et al. (1987)***, and if they can survive transplacental transmission, this may be a means of maintaining the spirochete in the rodent population in the absence of ticks.” – Burgess, 1993

“... these results indicated ***that B. burgdorferi can transmit by other modes than the tick bite***.” – Altaie et al, 1996

***“This could mean that a survey for Bb infection using the presence of antibodies alone as the method of detection may underestimate the prevalence of infection.”*** – Burgess et al, 1989.

“Intrauterine infection by *B. burgdorferi* does occur in dogs and is a potential means by which ***the spirochete can be transmitted in a breeding population in the absence of a tick vector***.” – Gustafson et al, 1993

“The findings of this study of natural *B. burgdorferi* infection in pregnant dairy heifers supports previous observations of both natural and experimental in-utero infections with *B. burgdorferi* in domestic animals and ***give further evidence of B. burgdorferi occurs during gestation*** in naturally infected cattle.” – Bushmich et al, 1998

“Vertical transmission of *B. burgdorferi* was confirmed with *B. burgdorferi* isolated from foetuses of *Apodemus agrarius* and *Rattus edwardsi*. ***The results showed that Lyme disease spirochetes might be naturally maintained in an enzootic cycle by transplacental transmission***.” - Wan et al, 1999.

# CDC 2020

The screenshot shows the CDC website's Lyme Disease page. The header includes the CDC logo and navigation links. The main content area is titled "Transmission" and contains text about the Lyme disease bacterium, *Borrelia burgdorferi*, and the blacklegged tick (*Ixodes scapularis*). It also includes a section titled "Relative sizes of blacklegged ticks at different life stages" with an image of four ticks (adult female, adult male, nymph, and larva) next to a dime coin for scale. The image shows the adult female tick is the largest, followed by the adult male, then the nymph, and the larva is the smallest. The text below the image states: "In general, adult ticks are approximately the size of a sesame seed and nymphal ticks are approximately the size of a poppy seed."

## Are there other ways to get Lyme disease?

- “Untreated Lyme disease during pregnancy can lead to infection of the placenta. Spread from mother to fetus is **possible but rare**.
- **Fortunately, with appropriate antibiotic treatment, there is no increased risk of adverse birth outcomes.**
- *There are no published studies assessing developmental outcomes of children whose mothers acquired Lyme disease during pregnancy.”*

# CDC 1985

## Current Trends Update: Lyme Disease and Cases Occurring during Pregnancy -- United States

MMWR June 28, 1985 / 34(25);376-8,383-4

“...CDC have **established a registry** to enroll cases of Lyme disease in pregnant women before the outcome of pregnancy is known. Of the **19 pregnancies** evaluated to date, none resulted in a child with a congenital heart defect. **However, other adverse outcomes were found, including intrauterine fetal demise in the second trimester, prematurity, and developmental delay with cortical blindness.** None of the adverse outcomes have been documented to be caused by Lyme disease. **Outcomes of 14 of the pregnancies were completely normal.** The risk of adverse outcome for pregnancies complicated by Lyme disease is not currently known.

**5 of 19 (26%) pregnancies had adverse outcomes**

# Adverse fetal outcomes in pregnant moms with Lyme disease

“...appraised by fetal loss and stillbirth, pre-term birth, offspring malformations...”

2010

“Adverse outcomes” in **12%** of IV treated moms; **31.6%** of oral treated moms; and **60%** of untreated moms

International Journal of Infectious Diseases 34 (2010) 1–6

Contents lists available at ScienceDirect  
International Journal of Infectious Diseases  
journal homepage: www.elsevier.com/locate/ijid

ELSEVIER

Maternal Lyme borreliosis and pregnancy outcome  
Andrić Lakšić<sup>a,\*</sup>, Norbert Solyom<sup>b</sup>

<sup>a</sup> The Center for Tick-borne Diseases, Hajdučki 14, Bolunovo, 61103, Zagreb  
<sup>b</sup> Department in Clinical Change Research Group, 100-010, 10000, St. 41, Budapest, 11118, Hungary

ARTICLE INFO

Article history:  
Received 10 April 2009  
Received in revised form 20 May 2009  
Accepted 27 July 2009

Corresponding author: William Coleman, William.Coleman@utoronto.ca

Keywords:  
Lyme disease  
Borrelia burgdorferi  
Pregnancy outcome  
Pregnancy loss

SUMMARY

**Background:** There is disagreement regarding whether Lyme borreliosis is associated with adverse pregnancy outcomes.

**Methods:** We performed a review of the data from 93 women with Lyme borreliosis during pregnancy, evaluated at the Center for Tick-borne Diseases, Budapest over the past 23 years.

**Results:** Treatment was administered parenterally to 50 (53.7%), women and orally to 43 (46.3%), infections remained untreated in 16 (17.2%) pregnancies. Adverse outcomes were seen in 54% (51/93) potentially treated women, 67% (31/46) orally treated women, and 60% (26/43) untreated women. In comparison to patients treated with antibiotics, untreated women had a significantly higher risk of adverse pregnancy outcome (odds ratio 1.88, 95% CI 0.89), while women treated orally had an increased chance (OR 3.71) of having an adverse outcome compared to those treated parenterally. This difference was not statistically significant ( $p = 0.07$ ); erythema migrans did not interfere by the end of the first antibiotic course in 17 patients. Adverse pregnancy outcome was more frequent among those whose organism remained untreated (OR 1.85), but this was not statistically significant ( $p = 0.147$ ). Loss of the pregnancy ( $n = 1$ ) and congenital neuroborreliosis ( $n = 4$ ) were the most frequent adverse outcomes in our series. The other complications were hematogenous.

**Conclusions:** Our results indicate that an untreated maternal *Borrelia burgdorferi* s.l. infection may be associated with an adverse outcome, although historical evidence of the true causal link is weak. It appears that a specific epidemic representing untreated Lyme borreliosis is unlikely.

© 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

**1. Introduction**

Lyme borreliosis is the most frequent vector-borne illness in the temperate zone of the northern hemisphere. Early publications suggested that, like syphilis, maternal *Borrelia burgdorferi* s.l. infection may adversely influence the outcome of pregnancy. Stillbirth and congenital heart abnormalities have been described.<sup>1–4</sup> With the exception of some publications,<sup>5,6</sup> most early case reports have described patients with adverse outcomes following their pregnancies. Incidence and cross-sectional studies on populations of 1000–5000 pregnant women and/or their offspring found hardly any cases of Lyme borreliosis and, therefore, remained inconclusive with respect to risk for adverse pregnancy outcomes.<sup>7–11</sup> Epidemiological evaluations of treated and untreated patients is also complicated by the low rate of untreated cases present and identified in most populations.<sup>12</sup> In the largest study to date on gestational Lyme borreliosis, almost every patient was treated with ceftriaxone.<sup>13</sup> Many years ago,

analysis of not recorded data suggested that untreated Lyme patients had a much greater chance of suffering an adverse outcome in pregnancy. But the number of patients was too low to achieve meaningful results.<sup>14</sup>

The Center for Tick-borne Diseases, Budapest was opened in 1980 under the leadership of one of the authors (AL). Since then, 8349 erythema migrans (EM) patients have been seen, including 87 cases in which *Borrelia burgdorferi* s.l. infection was clinically evident during pregnancy. Here we report our experience with these cases.

**2. Methods**

**2.1. Patients**

From the 87 reported cases of gestational Lyme disease, we were able to analyze 93. Two women were lost to follow-up before delivery. All women were seen by the same physician (AL). The following criteria for inclusion were used: (1) EM both during pregnancy, as defined by the Centers for Disease Control and Prevention (CDC)<sup>15</sup> and the European Union Coordinated Action on Lyme Borreliosis (CALB);<sup>16</sup> (2) criteria ( $n = 12$ ); (3) Patients were

\* Corresponding author. Tel.: +36 36 361120; fax: +36 31 355600.  
E-mail address: andriac@iinf.hu (A. Lakšić).

1551-0717/\$36.00 – see front matter © 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.  
doi:10.1016/j.ijid.2009.07.004

2018

“Adverse outcomes” in **11%** of treated moms and **50%** of untreated moms

PLOS ONE

RESEARCH ARTICLE

A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn

Lisa A. Wasdell<sup>1\*</sup>, Judy Geig<sup>1</sup>, L. Robbin Lindsay<sup>2</sup>, Alison F. Hinkley<sup>3</sup>, Nicholas H. Ogden<sup>4</sup>

<sup>1</sup> National Microbiology Laboratory, Public Health Agency of Canada, Guelph, Ontario, Canada, <sup>2</sup> National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, <sup>3</sup> Center for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, Fort Collins, Colorado, United States of America, <sup>4</sup> National Microbiology Laboratory, Public Health Agency of Canada, Saint-Hyacinthe, Quebec, Canada

\* lisa.wasdell@ph.gc.ca

Check for updates

OPEN ACCESS

**Citation:** Wasdell LA, Geig J, Lindsay LJ, Hinkley AF, Ogden NH (2018) A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn. PLOS ONE 13(11): e0207677. doi:10.1371/journal.pone.0207677

**Editor:** R. Mark Nisbet, University of Toledo College of Medicine and Life Sciences, UNITED STATES

**Received:** August 27, 2018  
**Accepted:** October 24, 2018  
**Published:** November 12, 2018

**Copyright:** © 2018 Wasdell et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and Supporting Information files.

**Funding:** The authors received no specific funding for this work.

**Competing Interests:** The authors have declared that no competing interest exist.

**Abstract**

Lyme disease (LD), caused by bacteria of the *Borrelia burgdorferi sensu lato* species complex, is the most common vector-borne disease in North America and Europe. A systematic review (SR) was conducted to summarize the global literature on adverse birth outcomes associated with gestational LD in humans. The SR followed an a priori protocol of pretested screening, risk of bias, and data extraction forms. Data were summarized descriptively and random effects meta-analysis (MA) was used where appropriate. The SR identified 45 relevant studies, 29 describing 59 cases reported as gestational LD in the United States, Europe, and Asia (1969–2017). Adverse birth outcomes included spontaneous miscarriage or fetal death ( $n = 12$ ), newborn death ( $n = 4$ ), and newborns with an abnormal outcome (e.g. hyperbilirubinemia, respiratory distress and syndactyly) at birth ( $n = 16$ ). Only one report provided a full case description (clinical manifestations in the mother, negative outcome for the child, and laboratory detection of *B. burgdorferi* in the child); the precludes some evidence for vertical transmission of *B. burgdorferi* has negative consequences for the fetus. The results of 17 epidemiological studies are included in the SR. Prevalence of adverse birth outcomes in an exposed population (defined by the authors as: gestational LD, history of LD, tick bites or residence in an endemic area) was compared to that in an unexposed population in eight studies and no difference was reported. A meta-analysis of nine studies showed a significantly lower adverse birth outcomes in women reported to have been treated for gestational LD (11%, 95% CI 7–16) compared to those who were not treated during pregnancy (50%, 95% CI 30–70) providing indirect evidence of an association between gestational LD and adverse birth outcomes. Other risk factors investigated, time of exposure, length of LD during pregnancy, acute vs. disseminated LD of diagnosis, and symptomatic LD vs. asymptomatic women with no LD symptoms during pregnancy were not significantly associated with adverse birth outcomes. This SR summarizes evidence from case studies that provide some limited evidence for transplacental transmission of *B. burgdorferi*. There was inconsistent evidence for adverse birth outcomes of gestational LD in the

PLOS ONE | <https://doi.org/10.1371/journal.pone.0207677> November 12, 2018

1 / 17

2020

“Adverse outcomes” in **14%** of IV treated moms. All pregnant moms were treated

Journal of Clinical Medicine

MDPI

Article

Course and Outcome of Erythema Migrans in Pregnant Women

Vera Maraspin<sup>1</sup>, Lara Lusa<sup>2,3</sup>, Tanja Blejcar<sup>4</sup>, Eva Rušič-Sabljic<sup>5</sup>, Maja Pohar Perme<sup>6</sup> and Franc Stie<sup>1,4\*</sup>

<sup>1</sup> Department of Infectious Diseases, University Medical Center Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia; vera.maraspin@uklj.si  
<sup>2</sup> Department of Mathematics, Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Glagoljaška 8, 6000 Koper, Slovenia; lara.lusa@upr.si  
<sup>3</sup> Institute for Biostatistics and Medical Informatics, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia; maja.pohar@mf.uni-lj.si  
<sup>4</sup> Department of Parasitology, University Medical Center Ljubljana, Štajerskeva ulica 6a, 1525 Ljubljana, Slovenia; tanja.blejcar@gmail.com  
<sup>5</sup> Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia; eva.rusic-sabljic@mf.uni-lj.si  
<sup>6</sup> Correspondence: franc.stie@uklj.si; Tel.: +386-1-522-21-10

Received: 3 July 2020; Accepted: 23 July 2020; Published: 24 July 2020

check for updates

**Abstract:** Information on Lyme borreliosis (LB) during pregnancy is limited. In the present study, the course and outcome of erythema migrans (EM) in 304 pregnant women, diagnosed in the period 1990–2015, was assessed and compared with that in age-matched non-pregnant women. The frequency of unfavorable outcome of pregnancies was also evaluated. The pregnant women reported constitutional symptoms less frequently than the non-pregnant women (22.4% vs. 37.2%,  $p < 0.001$ ). Pregnant women diagnosed with EM later during pregnancy had a lower probability of reporting constitutional symptoms (odds ratio = 0.97 for 1-week difference in gestation week at diagnosis of EM, 95% CI: 0.94–0.99,  $p = 0.02$ ). The outcome of pregnancy was unfavorable in 42/304 (13.8%) patients: preterm birth in 22/42 (52.4%), fetal/perinatal death in 10/42 (23.8%), and/or anomalies in 15/42 (35.7%). Several patients had potential explanation(s) for the unfavorable outcome. In conclusion, the course of early LB during pregnancy is milder than in age-matched non-pregnant women. The outcome of pregnancy with the treatment approach used in the present study (i.e. ceftriaxone 2 g once daily for 14 days) is favorable.

**Keywords:** erythema migrans; Lyme borreliosis; gestation; pregnancy outcome; *Borrelia burgdorferi sensu lato*

**1. Introduction**

Lyme borreliosis (LB) usually presents as the skin lesion erythema migrans (EM). The lesion, which is the result of tick bite inoculation of *Borrelia burgdorferi sensu lato* (s.l.) into the skin, develops early in the course of the disease. The causative agent can disseminate in some patients, resulting in secondary skin lesions and involvement of the nervous system, joints, heart, and/or eye [1]. Information on LB during pregnancy is limited. According to general belief, there are no differences in the course of the disease in pregnant and non-pregnant women. However, a PubMed literature search has found no straightforward data on the course of the infection in pregnant women, and information on the outcome of their pregnancies is limited [2–23].

The aim of our study was to evaluate and compare the course and outcome of early LB in non-pregnant and pregnant women and to assess the outcomes of the pregnancies.

J. Clin. Med. 2020, 9, 2364; doi:10.3390/jcm9072364

www.mdpi.com/journal/jcm

Article

## Course and Outcome of Erythema Migrans in Pregnant Women

Vera Maraspin <sup>1</sup>, Lara Lusa <sup>2,3</sup>, Tanja Blejce <sup>4</sup>, Eva Ružič-Sabljic <sup>5</sup>, Maja Pohar Perme <sup>3</sup>  
and Franc Strle <sup>1,\*</sup>

<sup>1</sup> Department of Infectious Diseases, University Medical Center Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia; vera.maraspin@uklj.si

<sup>2</sup> Department of Mathematics, Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Glagoljaška 8, 6000 Koper, Slovenia; lara.lusa@famnit.upr.si

<sup>3</sup> Institute for Biostatistics and Medical Informatics, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia; maja.pohar@mf.uni-lj.si

<sup>4</sup> Department of Perinatology, University Medical Center Ljubljana, Štagnovjeva ulica 6a, 1525 Ljubljana, Slovenia; tanja.blejce@gmail.com

<sup>5</sup> Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia; eva.ruzic-sabljic@mf.uni-lj.si

\* Correspondence: franc.strle@uklj.si; Tel.: +386-1-522-21-10

Received: 3 July 2020; Accepted: 23 July 2020; Published: 24 July 2020



**Abstract:** Information on Lyme borreliosis (LB) during pregnancy is limited. In the present study, the course and outcome of erythema migrans (EM) in 304 pregnant women, diagnosed in the period 1990–2015, was assessed and compared with that in age-matched non-pregnant women. The frequency of unfavorable outcome of pregnancies was also evaluated. The pregnant women reported constitutional symptoms less frequently than the non-pregnant women (22.4% vs. 37.2%,  $p < 0.001$ ). Pregnant women diagnosed with EM later during pregnancy had a lower probability of reporting constitutional symptoms (odds ratio = 0.97 for 1-week difference in gestation week at diagnosis of EM, 95% CI: 0.94–0.99,  $p = 0.02$ ). The outcome of pregnancy was unfavorable in 42/304 (13.8%) patients: preterm birth in 22/42 (52.4%), fetal/perinatal death in 10/42 (23.8%), and/or anomalies in 15/42 (35.7%). Several patients had potential explanation(s) for the unfavorable outcome. In conclusion, the course of early LB during pregnancy is milder than in age-matched non-pregnant women. The outcome of pregnancy with the treatment approach used in the present study (i.v. ceftriaxone 2 g once daily for 14 days) is favorable.

**Keywords:** erythema migrans; Lyme borreliosis; gestation; pregnancy outcome; *Borrelia burgdorferi* sensu lato

### 1. Introduction

Lyme borreliosis (LB) usually presents as the skin lesion erythema migrans (EM). The lesion, which is the result of tick bite inoculation of *Borrelia burgdorferi* sensu lato (s.l.) into the skin, develops early in the course of the disease. The causative agent can disseminate in some patients, resulting in secondary skin lesions and involvement of the nervous system, joints, heart, and/or eye [1].

Information on LB during pregnancy is limited. According to general belief, there are no differences in the course of the disease in pregnant and non-pregnant women. However, a PubMed literature search has found no straightforward data on the course of the infection in pregnant women, and information on the outcome of their pregnancies is limited [2–23].

The aim of our study was to evaluate and compare the course and outcome of early LB in non-pregnant and pregnant women and to assess the outcomes of the pregnancies.

“In conclusion, the course of early LB during pregnancy is **milder than in age-matched non-pregnant women**. The **outcome of pregnancy** with the treatment approach used in the present study (i.v. ceftriaxone 2 g once daily for 14 days) is **favorable**.”

The outcome of pregnancy was **unfavorable in 42/304 (13.8%) of TREATED patients**

- Preterm birth in 22/42 (52.4%)
- Fetal/perinatal death in 10/42 (23.8%)
- Anomalies in 15/42 (35.7%).

# Syphilis and borreliosis during pregnancy

J. HERCOGOVA & D. VANOUSOVA

Dermatology Department, Charles University Prague, Czech Republic

**ABSTRACT:** Syphilis and Lyme borreliosis have similar etiologic, clinical, and epidemiologic characteristics. Both are multisystem infectious disorders spread worldwide. Their clinical course can be divided into three stages and as to spirochetal origin, antibiotic therapy is similar too. Taxonomical relationship of *Treponema* and *Borrelia* could explain also congenital manifestations well-known in syphilis, and suggested in borreliosis. Therapy of pregnant women with syphilis and Lyme borreliosis should follow the same strategy.

**KEYWORDS:** borrelia burgdorferi, Lyme borreliosis, pregnancy, syphilis, treponema pallidum

## Introduction

Syphilis is a multisystem infectious disease caused by *Treponema pallidum* acquired by sexual contact, it is a classical sexually transmitted disease distributed worldwide. Lyme borreliosis is a multisystem infectious disease caused by *Borrelia burgdorferi sensu lato* transmitted by ticks, it is the most frequent arthropod zoonosis distributed worldwide too. Both, *Treponema* and *Borrelia* belong to the order Spirochetales that are pathogenic to humans (1).

*T. pallidum* measures 12 µm in length and 0.15 µm in width. It has 8–10 coils on average, moves by rotation and flexes centrally. Its replication time is 33 hours. Syphilis is most frequent in people with a high sexual activity. Despite being reported worldwide, primary and secondary stages of the disease remain a problem, but tertiary and congenital syphilis have decreased in Western countries. On the contrary, they could significantly increase perinatal mortality rate in underdeveloped countries, including previous countries of the Soviet block (2). Another problem is an association of syphilis with other sexually transmitted infections, i.e., hepatitis B and C and HIV positivity. Syphilis infection in children is mainly caused by transplacental transmission; the infection during labor is not proved.

Address correspondence and reprint requests to: Prof. Jana Hercogova, MD, Dermatology Department, Charles University Prague, Bulovka University Hospital, Budinova 2, 180 81 Prague, Czech Republic, or email: Dermatology@fnb.cz.

Syphilis course is divided into three stages – primary, secondary, and tertiary. The typical ulcer durum lesion appears at the site of inoculation after approximately 3 weeks. Atypical clinical pictures of chancre are increasing, they can be present as multiple lesions with crust and tenderness. Firm and nontender enlargement of regional lymph nodes follows, and spontaneous healing occurs within 4–6 weeks. Six weeks later, secondary syphilis begins in 30–40% of untreated patients. It is caused by hematogenous spread of *T. pallidum* and it could involve all body organs. The main symptoms are generalized lymphadenopathy, influenza-like symptoms (headache, upper respiratory symptoms, pharyngitis, malaise, hepatosplenomegaly, etc.), mucocutaneous lesions (roseola syphiliticum, papulosquamous lesion on palms and soles, hypertrophic moist papule – condylomata lata, enanthems, alopecia, etc.). Tertiary syphilis occurs in one of six patients with untreated secondary syphilis. It could be neurosyphilis (6.5%), cardiovascular disease (10.5%), other (2%), and in 10.8% syphilis can be the primary cause of death (3).

*B. burgdorferi* measures 10–30 µm in length and 0.2–0.3 µm in width. It has 3–10 coils on average, moves by rotation and flexes centrally. Its replication time is 7–20 hours. Borreliosis is an infection of animals (rodents, deer, pigs, birds, etc.), transmitted to humans by *Ixodes* ticks. Its incidence varies according to the occurrence of infected animals and vectors. Despite being reported worldwide,

“Several spirochetes are known to cause transplacental infections in animals and humans. *T. pallidum* is the spirochete that has been the most known to cause congenital infection in humans. Adverse fetal outcomes have also been reported in gestational infections with *Leptospira canicola*, the etiologic agent of leptospirosis, and with *Borrelia* species including *Borrelia recurrentis*, the etiologic agent of relapsing fever (6). *B. burgdorferi* is a spirochete, thus congenital infection could be predicted.”

CDC Centers for Disease Control and Prevention  
CDC 24/7: Saving Lives. Protecting People™

A-Z Index  
Search  
Advanced Search

## Pregnancy and HIV, Viral Hepatitis, STD, & TB Prevention

NCHHSTP > Pregnancy Home > Challenges

- Pregnancy Home
- Overview
- Screening Recommendations +
- Effects and Burden +
- Challenges -
  - HIV
  - HBV
  - HCV

### Syphilis Challenges

Lack of prenatal care and gaps in testing and treatment among those who do receive prenatal care are significant challenges for preventing congenital syphilis.

#### Screening

Even among those receiving some prenatal care, the detection and treatment of maternal syphilis often occurs too late in pregnancy to prevent congenital syphilis. Health departments, in partnership with prenatal care providers and other local organizations, should work together to address barriers to obtaining early and adequate prenatal care for the most vulnerable pregnant women in their communities.

#### Access To and Availability of Treatment

- Lack of prenatal care and ***gaps in testing and treatment*** among those who do receive prenatal care are significant challenges for preventing congenital syphilis.
- Even among those receiving some prenatal care, ***the detection and treatment of maternal syphilis often occurs too late in pregnancy to prevent congenital syphilis.***

# Broaden the perspective to “Borreliosis” not just Lyme borreliosis?

MAJOR ARTICLE

## Complications of Pregnancy and Transplacental Transmission of Relapsing-Fever Borreliosis

Christer Larsson,<sup>1</sup> Marie Andersson,<sup>1</sup> Betty P. Cuo,<sup>1</sup> Annika Nordstrand,<sup>1</sup> Inga Hågerstrand,<sup>2</sup> Sara Carlsson,<sup>1</sup> and Sven Bergström<sup>1</sup>

Departments of <sup>1</sup>Molecular Biology and <sup>2</sup>Pathology, Umeå University, Umeå, Sweden

Relapsing fever borreliosis caused by *Borrelia duttonii* is a common cause of complications of pregnancy, miscarriage, and neonatal death in sub-Saharan Africa. We established a murine model of gestational relapsing fever infection for the study of the pathological development of these complications. We demonstrate that *B. duttonii* infection during pregnancy results in intrauterine growth retardation, as well as placental damage and inflammation, impaired fetal circulation, and decreased maternal hemoglobin levels. We show that spirochetes frequently cross the maternal-fetal barrier, resulting in congenital infection. Furthermore, we compared the severity of infection in pregnant and nonpregnant mice and show that pregnancy has a protective effect. This model closely parallels the consequences of human gestational infection, and our results provide insight into the mechanisms behind the complications of pregnancy that have been reported in human relapsing fever infection.

Infectious disease is one of the most common causes of complications of pregnancy and infant death in developing countries. Approximately 25% of neonatal deaths in Africa result from severe infections [1]. Complications such as spontaneous abortion and perinatal death as a consequence of tickborne relapsing fever (RF) have been well documented, with the majority of cases occurring in sub-Saharan Africa [2–9], although reports from developed countries also exist [10–12]. In the present study, we developed a mouse model to elucidate the mechanisms behind complications of pregnancy caused by the sub-Saharan RF agent *Borrelia duttonii*.

*Borrelia* spirochetes are transmitted by arthropods

and cause either Lyme disease or RF [13]. *B. duttonii*, the primary agent of RF in sub-Saharan Africa, is transmitted to humans by the tick *Ornithodoros moubata* [14]. The patient has a recurrent fever alternating with periods of relative well-being. The fever coincides with high numbers of borreliae in the blood. The relapsing pattern is due to antigenic variation of surface lipoproteins [15, 16]. Other symptoms include headache, abdominal pain, hemorrhage, hepatomegaly and splenomegaly, neurological manifestations, and weakness [17]. Unique to African tickborne *Borrelia* is the ability to form aggregates of erythrocytes and bacteria, called “rosetting” [18, 19], with subsequent disruption of the microcirculation [20]. Disease severity and mortality rates vary depending on the infecting strain and patient status but are generally highest in young children [17, 21].

As many as 6.4% of pregnant women admitted to a maternity ward in the Democratic Republic of the Congo received a diagnosis of RF [7]. Common complications of RF during pregnancy are low birth weight, preterm delivery, spontaneous abortion, and neonatal death [2–7, 9]. Two of the most severe consequences are pregnancy loss and neonatal death. *B. duttonii* causes preterm birth with a 30% risk of pregnancy loss, and rates of fetal/infant mortality of 15% [8] and 44%

Received 11 April 2006; accepted 2 June 2006; electronically published 3 October 2006.

Presented in part: Boston Research Conference for the Biology of Spirochetes, Ventura, California, 25–30 January 2004.

Financial support: Swedish Research Council (grant V04M 01522), Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, Swedish Foundation for Strategic Research, Infection & Vaccinology, Microbes and Man Research Programme, JC Kempe Foundation.

Potential conflicts of interest: none reported.

Reprints or correspondence: Dr. Sven Bergström, Umeå University Dept. of Molecular Biology, SE-901 87 Umeå, Sweden (sven.bergstrom@molbio.umu.se).

The Journal of Infectious Diseases 2006;194:1367–74

© 2006 by the Infectious Diseases Society of America. All rights reserved. DOI:10.1093/infdis/jih110

JAMA Network

JAMA

Search All

Enter Search Term

This Issue

Article

April 28, 1969

## Neonatal Relapsing Fever Due to Transplacental Transmission of Borrelia

Peter C. Fuchs, MD; Albert A. Oyama, MD

Author Affiliations

JAMA. 1969;208(4):690-692. doi:10.1001/jama.1969.03160040098019



Abstract

Transplacental transmission of relapsing fever occurred; spirochetes of the genus *Borrelia* were demonstrated in the blood of the mother and infant and in the cerebrospinal fluid (CSF) of the infant. Autopsy of the baby, who died 39 hours after birth, showed meningitis and typical splenic lesions with numerous spirochetes. Some unusual aspects of this case are the transplacental transmission, fatal outcome in the infant, and the demonstration of spirochetes in the CSF on direct smear.

*Borrelia miyamotoi* is a “relapsing fever” strain transmitted by the same ticks that transmit Lyme disease.



Supported by the U.S. Department of Health and Human Services • Office of the Assistant Secretary for Health

# Tick-Borne Disease Working Group

## 2018 Report to Congress

Information and opinions in this report do not necessarily reflect the opinions of each member of the Working Group, the U.S. Department of Health and Human Services, or any other component of the Federal Government.

- Transplacental transmission of the human fetus has been recognized for **relapsing fever borreliosis as well as Lyme disease...**
- Gestational tick-borne disease can be transmitted to unborn children in-utero and **has the potential to cause premature labor and fetal death.**
- Hormonal changes during pregnancy can **lead to changes in immune function that may affect detection of clinical or laboratory findings.**

<https://www.hhs.gov/sites/default/files/tbdwg-report-to-congress-2018.pdf>





Figure 1. The NIH Strategic Plan for TBD Research builds on the existing foundation of research and resources to advance five TBD research priorities targeted at 1) improving fundamental knowledge, 2) advancing diagnosis, 3) preventing new TBD infections, 4) improving treatment for all forms of TBDs, and 5) supporting tools and resources to advance priorities 1 through 4.

2<sup>nd</sup> Report

Supported by the U.S. Department of Health and Human Services • Office of the Assistant Secretary for Health

# Tick-Borne Disease Working Group

## 2020 Report to Congress

Information and opinions in this report do not necessarily reflect the opinions of each member of the Working Group, the U.S. Department of Health and Human Services, or any other component of the Federal government.



## Chapter 8

# Epidemiology and Surveillance

### Recommendations at a Glance: Epidemiology and Surveillance

-  **Recommendation 8.1:** Fund prospective studies of acute febrile illnesses to assess the burden of tick-borne diseases, including rickettsial, ehrlichial, and anaplasma pathogens.
-  **Recommendation 8.2:** Recommend that CDC work with Council of State and Territorial Epidemiologists (CSTE) to streamline the surveillance process and to reduce the burden on both clinicians and public health departments by permitting direct laboratory reporting of positive cases.
-  **Recommendation 8.3:** Further evaluation of non-tick bite transmission of Lyme disease, for example maternal-fetal transmission.

*“Further evaluation of non-tick bite transmission of Lyme disease, for example maternal-fetal transmission.”*

[https://www.hhs.gov/sites/default/files/tbdwg-2020-report\\_to-congress-final.pdf](https://www.hhs.gov/sites/default/files/tbdwg-2020-report_to-congress-final.pdf)

***“It is surprising that the evidence presented for transplacental transmission has received little notice by investigators. It would seem that the clinical and epidemiological implications, if significant, could have an impact on current thinking and measures taken to manage the disease.”***

Gustafson, John Michael, Ph.D. The in utero and seminal transmission of *Borrelia burgdorferi* in Canidae. The University of Wisconsin - Madison, 1993. PhD Thesis.